 beta-adrenergic-antagonist drug prevent gastrointestin bleed patient cirrhosi esophag varic analysi data prognost factor patient random clinic trial franco-italian multicent studi group background valu beta-adrenergic-antagonist drug therapi prevent initi episod gastrointestin bleed patient cirrhosi esophag varic uncertain posit neg studi result method studi data individu patient random trial efficaci treatment patient beta-adrenergic-antagonist drug propranolol nadolol placebo result year mean SE percentag patient upper gastrointestin bleed percent beta-adrenergic-antagonist treatment group percent control group percentag patient fatal bleed percent treatment group percent control group percentag patient year percent treatment group percent control group age sever cirrhosi account surviv rate treatment group percentag patient bleed year percent treatment group percent control group propranolol first episod sever cirrhosi presenc ascit bleed death group efficaci beta-adrenergic-antagonist therapi prevent bleed fatal bleed prevent death adjust caus sever cirrhosi ascit size varic conclus propranolol nadolol effect first bleed mortal rate gastrointestin bleed patient cirrhosi sever